Información del artículo
El tratamiento fibrinolítico ha mejorado significativamente el pronóstico de los pacientes con infarto agudo de miocardio. Pero esta estrategia terapéutica tiene limitaciones importantes como son: la escasa utilización, no conseguir óptima reperfusión en todos los pacientes y las complicaciones sobre todo hemorrágicas que en ocasiones pueden ser graves
Se están investigando fármacos que eviten o disminuyan estos problemas, que actúen más rápidamente, sean más fáciles de administrar, lo que facilitaría el uso prehospitalario, y que tengan más capacidad lítica y menores complicaciones hemorrágicas
Palabras clave:
fibrinolíticos
infarto agudo de miocardio
The fibrinolytic agents have improved significantly the prognosis of patients with acute myocardial infarction, but this therapy has significant limitations like: they remain underutilized, do not get an optimal reperfusion in all patients and they can cause complications, mainly bleeding, sometimes serious
There are under investigation newer drugs to prevent or decrease these problems, drugs that work faster and that are of easier administration. These new drugs would allow a prehospital use and they would have a greater lytic power and less bleedding complications
Key words:
Fibrinolytic agents
acute myocardial infarction
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.A. De Wood, J. Spores, R. Notske, L.T. Mouser, R. Burroughs, M.S. Golden, et al.
Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.
N Engl J Med, 303 (1980), pp. 897-901
[2.]
K.T. Rentrop, H. Blanke, K.R. Karsch.
Initial experience with transluminal recanalization of recenly occluded infarct-related coronary artery in acute myocardial infarction comparison with conventinally treated patients.
Clin Cardiol, 2 (1979), pp. 92-105
[3.]
Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocárdico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.
Lancet, 1 (1986), pp. 397-402
[4.]
Second International Study of Infact Survival (ISIS-2). Randomised trial of intravenous streptikinase oral aspirin, both or neither among 17.187 cases of suspected acute myocardial infarction.
Lancet, 2 (1988), pp. 349-360
[5.]
The GUSTO Investigators. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction.
N Engl J Med, 329 (1993), pp. 673-682
[6.]
The GUSTO angiographic Investigators.The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular function, and Survival after Acute Myocardial Infarction.
N Engl J Med, 329 (1993), pp. 1.650-1.652
[7.]
R. Smalling.
Molecular biology of plasminogen activators: what are the clinical implications of drug design?.
Am J Cardiol, 78 (1996), pp. 2-7
[8.]
Fibrinolytic Therapy Trialists (FTT) Colaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortalitymajor morbidity results from all randomised trials of more than 1000 patients.
The lancet, 343 (1994), pp. 311-322
[9.]
A. Cabadés, L. López-Bescós, F. Arós, A. Loma-Osorio, X. Bosch, P. Pabón, et al.
Variabilidad en el manejo y pronóstico a corto y medio plazo del infarto de miocardio en España: el estudio PRIAMHO.
Rev Esp Cardiol, 52 (1999), pp. 767-775
[10.]
E. Aguayo, A. Reina, M. Colmenero, M. Barranco, M. Pola, M. Jiménez, grupo ARIAM.
Análisis de los retrasos en el tratamiento del síndrome coronario agudo. Datos del registro ARIAM.
Med Intensiva, 23 (1999), pp. 280-287
[11.]
M. Siches, X. Bosch, A. Betriu.
Optimización del tratamiento trombolítico en el infarto agudo de miocardio: papel de los nuevos fármacos fibrinoselectivos y de la asociación con los nuevos antitrombóticos.
Rev Esp Cardiol, 51 (1998), pp. 178-191
[12.]
K. Stringer.
Biochemical and pharmacologic comparison of thrombolytic agents.
Pharmacotherapy, 16 (1996), pp. 1.195-1.265
[13.]
D. Gulba, C. Bode, M. Runge, K. Huber.
Thrombolytic agents – an overview.
Ann Hematol, 73 (1996), pp. S9-S27
[14.]
S. Noble, D. Mc Tavish.
Reteplase a review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
Drugs, 42 (1996), pp. 589-605
[15.]
W. Weaver.
The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
Eur Heart J, 17 (1996), pp. 9-15
[16.]
R. Smalling.
Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.
Eur Heart J, 18 (1997), pp. F11-F16
[17.]
R. Smalling, C. Bode, J. Kalbfleisch, S. Sen, P. Limbourg, F. Forycki, the Rapid investigators.
More Rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction.
Circulation, 91 (1995), pp. 2.725-2.732
[18.]
C. Bode, R. Smalling, G. Berg, C. Burnett, G. Lorch, J. Kalbfleisch, the RAPID II investigators.
Randomized comparison of coronary thrombolytisis achieved with double-bolus reteplase (recombinant plasminogen activator) in patients with acute myocardial infarction.
Circulation, 94 (1996), pp. 891-898
[19.]
International Joint Efficacy Comparison of thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence.
Lancet, 346 (1995), pp. 329-336
[20.]
The GUSTO III Investigators. A comparison of Reteplase with Alteplase for acute myocardial infarction.
N Engl J Med, 337 (1997), pp. 1.118-1.123
[21.]
P. Gurbel, V. Serebruany, A. Shustov, R. Bahr, C. Carpo, E. Ohman.
Effects of reteplase and alteplase on platelet aggregation and mayor receptor expression during the first 24 hours of acute myocardial infarction treatment.
J Am Coll Cardiol, 31 (1998), pp. 1.466-1.473
[22.]
R. Califf.
Glycoprotein IIb/IIIa blockade and thrombolytics: Early lessons from the SPEED and GUSTO IV trials.
Am Heart J, 138 (1999), pp. S12-S15
[23.]
C. Benedict, D. Phil, C. Refino, B. Keit, R. Pakala, N. Poni.
New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bledding caompared with recombinant human TPA.
Circulation, 92 (1995), pp. 3.032-3.040
[24.]
C. Cannon, C. McCabe, M. Gibson, M. Ghali, R. Sequena, E. Braunwald, the TIMI 10A investigators.
TNK-Tissue Plasminigen Activator in Acute Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI 10 A) Dose-Ranging Trial.
Circulation, 95 (1997), pp. 351-356
[25.]
C.H. Cannon, C. Gibson, Cabe C Mc, A. Adgey, M. Scheweiger, E. Braunwald, the TIMI 10B investigators.
TNK-Tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction.
Circulation, 98 (1998), pp. 2.805-2.814
[26.]
F. Van de Werf, C. Cannon, A. Luyten, K. Houbracken, C. Mc Cabe, S. Berioli, et al.
For the ASSENT-1 investigators. Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial.
Am Heart J, 137 (1999), pp. 786-791
[27.]
F. Van de Werf, J. Adjey, D. Ardissino, P. Armstrong, Ph Aylward, G. Barbash, et al.
For the ASSENT-2 trial investigators. Single- bolus tenectelase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
Lancet, 354 (1999), pp. 716-722
[28.]
H. White, F. Van de Werf.
Thrombolysis for acute myocardial infarction.
Circulation, 97 (1998), pp. 1.632-1.646
[29.]
P. Heijer, F. Vermeer, E. Ambrosioni, Z. Sadowoki, Sendón JL Lopez, R. Van Essen, of the In-TIME investigators group.
Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction. A double-blind randomized angiographic trial of lanoteplase versus alteplase.
Circulation, 98 (1998), pp. 2.117-2.125
[30.]
A. Ross.
New Plasminogen Activators: A clinical Review.
Clin Cardiol, 22 (1999), pp. 165-171
[31.]
M. Verstraete, H. Lijnen.
Novel Thrombolytic Agents.
Cardiovasc Drugs Ther, 8 (1994), pp. 801-812
[32.]
PRIMI Trial Study Group. Randomised Double-Blind Trial of Recombinant Pro-urokinase against Streptokinase in Acute Myocardial Infarction.
Lancet, 1 (1989), pp. 863-867
[33.]
H. Ostermann, H. Schmitz-Huebner, J. Windeler, F. Bar, J. Meyer, J. Van de Loo, for the PRIMI Trial Study Group.
Rate of fibrinogen breakdown related to coronary patency and Bleeding complications in patients with thrombolysis in acute myocardial infarction. Results from the PRIMI Trial.
Eur Heart J, 13 (1992), pp. 1.225-1.232
[34.]
J. Schofer, M. Lins, G. Mathey, F. Sheehan, the PRIMI Trial Study Group.
Time course of left ventricular function and coronary patency after saruplase vs streptokinase in acute myocardial infarction.
Eur Heart J, 14 (1993), pp. 958-963
[35.]
M. Spiecker, J. Windeler, F. Vermeer, R. Michels, R. Seabra-Gomes, J. Von Dahl, et al.
Thrombolysis with Saruplase versus Streptokinase in acute myocardial infarction: Five-year results of the PRIMI trial.
Am Heart J, 138 (1999), pp. 518-524
[36.]
F. Bär, J. Meyer, F. Vermeer, R. Michels, B. Charbonnier, K. Haerten, for the SESAM Study Group, et al.
Comparison of Saruplase and Alteplase in Acute Myicardial Infarction.
Am J Cardiol, 79 (1997), pp. 727-732
[37.]
U. Tebbe, R. Michels, J. Adgey, J. Boland, A. Caspi, B. Chanbonnier, for the COMASS Investigators, et al.
Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial of saruplase and streptokinase.
J Am Coll Cardiol, 31 (1998), pp. 487-493
[38.]
D. Collen, R. Bernaerts, P. Declerck, F. De Cock, E. Demarsin, J. Stephane, et al.
Recombinant Staphylokinase variants With Altered Inmunoreactivity: construction and characterization.
Circulation, 94 (1996), pp. 197-206
[39.]
S. Vanderschueren, D. Collen, F. Van de Werf.
A Pilot Study on bolus Administration of Recombinant Staphylokinase for Coronary Artery Thrombolysis.
Thromb Haemost, 76 (1996), pp. 541-544
[40.]
S. Vanderschueren, J. Dens, P. Kerdsinchai, W. Desmet, M. Vrolix, F. De Man, et al.
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.
Am Heart J, 134 (1997), pp. 213-219
[41.]
S. Bleich, A. Adgey, R. Mc Mechan, T. Love.
for the doublebolus study investigators and angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction.
Am Heart J, 136 (1998), pp. 741-748
[42.]
F. Van de Wer, the COBALT investigators.
A Comparison of continuos infusion of alteplase with double-bolus administration for acute myocardial infarction.
N Engl J Med, 337 (1997), pp. 1.124-1.130
[43.]
D. Gulba, P. Tanswell, R. Dechend, M. Sosada, A. Weis, J. Waigand, et al.
Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
J Am Coll Cardiol, 30 (1997), pp. 1.611-1.617
[44.]
S. Zarich, G. Kowalchuk, D. Weaver, J. Loscalzo, M. Sassower, K. Manzo, for the PATENT study group.
Sequential combination thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial.
J Am Coll Cardiol, 26 (1995), pp. 374-379
[45.]
J. Ferguson, K. Taqi.
IIb/IIIa Receptor blockade in acute myocardial infarction.
Am Heart J, 138 (1999), pp. S164-S170
Copyright © 2000. Sociedad Española de Medicina Intensiva, Critica y Unidades Coronarias (SEMICYUC) and Elsevier España, S.L.
